1H 2022 Pharma Sector Snapshot
To take a deeper dive in to what we’ve seen so far in 2022 and our outlook for the second half of the year, read our full Pharma Sector Snapshot. Even with regulatory headwinds and a challenging economic environment, quality assets are trading at premium valuations. As we move into the second half of 2022, Big Pharma balance sheets are flush with cash and we expect to see sustained M&A interest as investors continue to deploy capital into private markets.
Compare to our 1H Pharma Services Sector Snapshot here.Click here to view this report in its entirety.